Harnessing the CD24/Siglec-10 pathway: immunotherapy innovation
Drug Target Review
OCTOBER 17, 2024
While its involvement in the do-not-eat-me signal from cancer has inspired therapeutic development of this pathway for oncology, the function of the innate immune checkpoint we identified in 2009 1 extends to both innate and adaptive immune responses. Biomarkers are the holy grail of clinical trials.
Let's personalize your content